immunotherapy

Michael Gibson, MD, PhD
October 30, 2024

Michael Gibson votes with FDA panel to limit immunotherapy indication 

The panel determined that allowing the wider indication would put patients at risk for adverse reactions from the two immunotherapies but without the added benefit in survival. 

By Tom Wilemon
(iStock)
October 4, 2024

‘Off-the-shelf’ CAR-T therapy shows promise for relapsed/refractory multiple myeloma 

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

By Tom Wilemon
October 2, 2024

Grant funds quest to expand immunotherapy efficacy for colorectal cancer  

The study seeks to understand the mechanisms of colorectal cancer and builds on recent Vanderbilt research.

By Tom Wilemon
July 10, 2024

Clinical trial for rectal cancer subtype shows promise for less aggressive treatment

The findings were so promising that the clinical trial is being redesigned to investigate whether radiation treatment can also be avoided.

By Tom Wilemon
June 12, 2024

Obesity-cancer connection discovery suggests strategies for improving immunotherapy 

The study reported in the journal Nature provides a mechanistic explanation for the “obesity paradox” — that obesity can contribute to cancer progression but also improve response to immunotherapy.

By Leigh MacMillan
Abigail Lindsey Rich talks about her research poster with Vanderbilt-Ingram Cancer Center director Ben Ho Park, MD, PhD. (photo by Donn Jones)
May 30, 2024

Speakers share history of hereditary cancers at scientific retreat 

Speakers at the Vanderbilt-Ingram Cancer Center 25th Annual Scientific Retreat detailed the history of hereditary cancer discoveries and gave overviews about ongoing research. 

By Tom Wilemon
April 24, 2024

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.
By Tom Wilemon
March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 
By Tom Wilemon
March 5, 2024

GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy

The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy.
By Tom Wilemon
February 16, 2024

Waddell Walker Hancock Cancer Discovery Fund names first scholars

A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund.
By Tom Wilemon
January 16, 2024

Data haul improves immunotherapy response prediction

Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.
By Paul Govern
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
December 11, 2023

Colorectal cancer ‘cartography’ reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body’s immune system.
By Bill Snyder
1 2 3 … 5